Moderna, Inc.
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Net product sales — Total commercial vaccines by Year
Net product sales — Total commercial vaccines ($M) ($M)
Moderna Net product sales — Total commercial vaccines: $1,818M in FY2025, down 41.5% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-Q / 10-K Consolidated Statements of Operations & Note 2.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net product sales — Total commercial vaccines ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,818 | -41.5% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 3,109 | -53.4% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 6,671 | -63.8% | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 18,435 | +4.3% | Form 10-K (filed 2025-02-21) ↗ |
| FY2021 | Dec 31, 2021 | 17,675 | +8,737.5% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 200 | – | Form 10-K (filed 2023-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 0 | – | Form 10-K (filed 2022-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 0 | – | Form 10-K (filed 2021-02-26) ↗ |
Breakdown
What makes up net product sales — Total commercial vaccines
- COVID-19 vaccines (Spikevax / mRNA-1273 & mNEXSPIKE / mRNA-1283) — Net product sales ($M)1,810 · FY2025
- RSV vaccine (mRESVIA / mRNA-1345) — Net product sales ($M)8 · FY2025
- Net product sales — United States ($M)1,165 · FY2025
- Net product sales — Europe ($M)50 · FY2025
- Net product sales — Rest of World ($M)603 · FY2025
- Approved commercial products on market (products)3.00 · FY2025
Cite this data
StockData. (2026). Moderna Net product sales — Total commercial vaccines ($M), annual FY2018–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/rev-product-sales
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.